Dr. Nanda explains the importance of copper metabolism in the body, disorders which can affect the body's copper metabolism, and means of testing for those disorders.


Download Slides (pdf)


Download Transcript (pdf)

Slide 1

Hello, my name is Dr.Rachita Nanda. I am an Additional Professor, Department of Biochemistry, All India Institute of Medical Sciences Raipur, India. Welcome to this Pearl of Laboratory Medicine on “Disorders of Copper Metabolism.”

Slide 2

The outline of this presentation is as follows. I will cover copper metabolism followed by some disorders of copper metabolism which will be discussed under pathogenesis, clinical features and diagnosis and treatment.

Slide 3

Copper is an important trace element of the biological systems with a requirement of 1- 2mg/day. Its absorption, distribution and elimination are highly regulated. It has multitude functions that starts with its ability to adopt two different redox states—in the oxidized (Cu2+) and reduced (Cu+) serving as a catalytic cofactor in redox chemistry like the cytochrome C oxidase in electron transport chain to provide energy. Other enzymes like superoxide dismutase, a free radical scavenger, ferroxidase for iron absorption, dopamine beta hydroxylase for catecholamine synthesis, monoamine oxidase for catecholamine metabolism, tyrosinase for pigment formation and lysyl oxidase for tissue integrity also depend on copper. There are also some copper dependent transcription factors that regulate gene expression.

Slide 4

Absorption of copper takes place primarily in the duodenum, the absorption not being influenced by the amount of copper stored in the body. The copper transporter receptor 1 (CTR1) is responsible for uptake of copper by intestinal epithelial cells. A major portion (25-60%) is transported out by ATP7A (a transmembrane copper-transporting P- type ATPase, mutated in Menke’s disease) to the basolateral surface, into the portal circulation and to liver. This protein is expressed in the intestine and other tissues but not the liver. In other tissues, ATP7A supplies copper to the organelles to synthesize certain enzymes like peptidyl-α-monooxygenase, tyrosinase and lysyl oxidase. The rest of the copper gets bound to metallothionein and is lost in feces during shedding of intestinal epithelial cells with a small amount also lost in urine. In the liver, the copper can be stored, or carried, by binding to apoceruloplasmin as ceruloplasmin to sytemic circulation or is excreted into intestinal lumen after biliary excretion.

Slide 5

The copper enters the liver through CTR1 and then gets complexed with metallothionein or glutathione Copper is helped by various chaperone proteins and is carried to specific proteins and organelles for synthesis of certain cellular enzymes. It also gets incorporated to apoceruloplasmin at the trans-Golgi apparatus with the help of ATP7B transmembrane copper-transporting P-type ATPase protein, (a product of Wilson’s disease gene) to form ceruloplasmin that enters into systemic circulation. In response to increased hepatocellular copper content, the ATP7B relocates to a vesicular compartment close to the canalicular membrane to cause biliary copper excretion. Whenever, the copper concentration is low, ATP7B incorporates copper into apoceruloplasmin to generate holoceruloplasmin but at high copper concentrations it expedites excretion of copper through the biliary system. Thus ATP7B acts as a sensing and monitoring device for copper within hepatocytes. The copper-glutathione complex through canalicularmutispecific organ anion transporter, is another minor route of hepatocellular copper excretion.

Slide 6

There are two disorders; inborn errors of copper metabolism which are well characterized but rare in nature. These are: Wilson’s disease and Menkes disease. Both these disorders are as a result of mutation in the copper-transporting P-type ATPases; ATP7B and ATP7A, respectively. Further there is a group of disorders that are a combination of environmental and genetic causes. These are the infantile and Idiopathic copper toxicosis and Tyrolean infantile cirrhosis.

Slide 7

Wilson’s disease is a monogenic autosomal recessive disorder of copper toxicity. The mutation that can result in structural or functional defects in the protein both of which can cause severe disease. As mentioned earlier, the product of this gene, ATP7B is required for synthesis of enzymatically active ceruloplasmin and biliary copper excretion. Impaired function of this protein results in reduced excretion of copper leading to pathologic accumulation in liver. The excess copper in liver exceeds the storage capacity of metallothionein, so copper gets deposited in lysosomes which through oxidative stress and free radicals mediate the damage of liver mitochondria resulting in hepatocyte inflammation and damage. This spills over to plasma with toxicity of the extrahepatic organs including brain, cornea and erythrocytes.

Slide 8

The major presentation in Wilson’s disease involves hepatic, neurological and psychiatric, ophthalmological and renal systems. Hepatic presentation like fatigue, anorexia, abdominal pain, nausea, jaundice (self-limiting), severe coagulopathy and encephalopathy are observed due to hepatic steatosis, inflammation, fibrosis, cirrhosis and liver failure. Coombs negative hemolytic anemia results from direct toxic effects of copper on red cell membranes. Copper gets deposited in brain primarily in the basal ganglia which results in symptoms of Parkinsonism like dysarthria, clumsiness, tremor, drooling, gait disturbances, mask like facies and deterioration of writing. Sometimes psychiatric symptoms like changes in personality, depression and anxiety can be observed. The ophthalmologic symptoms show the presence of copper and sulfur rich granules in the Descemet membrane of cornea giving a golden brown ring or a greenish discoloration in the limbus, known as the Kayser-Fleischer Ring, under slit lamp.The associated renal symptoms can be microscopic hematuria or Fanconi syndrome.

Slide 9 and Slide 10

The Leipzig criteria published by the European Association for the Study of the Liver and validated in adults and children, should be used for the diagnosis of Wilson’s disease, considers both the clinical and laboratory data to establish the diagnosis. The clinical data includes presence of Kayser-Fleischer rings and neurological manifestations. The laboratory testing includes ceruloplasmin, urine copper, hepatic copper, coombs test for hemolytic anemia and molecular testing for ATP7B mutations. When a score of 1-2 is achieved it excludes Wilson’s disease while a score of 3 suggests further evaluation. The diagnosis is established after achieving at least 4 points.

Slide 11

There are more than 600 mutations of ATP7B gene. The majority of mutations are missense mutations, with few mutations for specific populations. It is very rare to find large deletions. When mutations at both alleles are identified in the proband, accurate diagnosis of Wilson disease can be made. Direct genetic testing, focusing on sequence analysis of ATP7B mutation hotspots are the mode of detection of mutations.

Slide 12

Copper chelators like penicillamine; promote excretion of copper in urine. Inhibits accumulation of copper in hepatocellular lysosomes and solubilizes copper for mobilization from these particles. It also inhibits collagen cross-linking and has some immunosuppressive properties. Trientine, or triethylenetetraminedihydrochloride, is the usual second-line treatment for patients who are intolerant of d-penicillamine. Trientine chelates copper and increases urinary copper excretion and may interfere with intestinal absorption of copper. Zinc salts increases metallothionein protein synthesis in intestine to trap the copper deposited in the intestinal cells so that it gets excreted in feces. As penicillamine is a pyridoxine antagonist, supplementation with this vitamin is recommended. In extreme cases of liver failure, there may be a need of liver transplantation. However, early detection and with good compliance to treatment, there is excellent prognosis of this disease.

Slide 13

Menkes disease is an X-linked inherited recessive disease caused by mutation of ATP7A gene. This gene is expressed in all tissues except the liver. ATP7A protein along with the ATP7B protein function as sensors of intracellular copper concentration. ATP7A acts as an intracellular pump to transport copper into the trans-Golgi network for incorporation into copper requiring enzymes including dopamine beta–hydroxylase and also mediates copper removal from cells.

Slide 14

Mutations of this gene are associated with loss of functions, with defective copper transport across intestine, brain and placenta. In the intestine there is accumulation of excess copper due to failure of copper efflux, resulting in systemic copper insufficiency and reduced activities of carious copper dependent enzymes. At the blood brain barrier copper efflux is hampered resulting in accumulation of copper in these cells and therefore failure of copper uptake in the brain.

Slide 15

The associated clinical features include hypothermia, neuronal degeneration in cerebral hemispheres, cerebellum and spinocerebellar tracts with associated demyelination, mental retardation, failure to thrive. Cherubic face with abnormalities in hair which is steely and depigmented (scalp hair called kinky or steel wool). Skeletal changes due to connective tissue defect like flaring and cupping of ribs and lateral and medial spur formation on the proximal or distal femoral and humoralmetaphyses with bone fractures. Low levels are found in, for example, plasma, liver, and brain, while excessive accumulation has been documented in other tissues, such as intestinal mucosa, kidney and placenta.

Slide 16

There is no single sensitive and specific test for diagnosing copper related diseases. The serum copper and ceruloplasmin are decreased which is reliable only beyond 6 weeks of life. Decreased hepatic copper and increased urine copper excretion is observed. Early detection can be facilitated by elevated dihydroxyphenylalanine(DOPA) and diydroxyphenylacetic acid(DOPAC) with reduced neurochemicals like epinephrine and nor-epinephrine and of their metabolites. Defective function of dopamine beta hydroxylase also leads to increased urine ratios of HVA/VMA. There is increased urine excretion of β2- microglobulin.

Slide 17

Diverse mutations are seen in ATP7A in Menkes disease. It is advisable that copper histidinate be administered as early as possible. In absence of early diagnosis and treatment prognosis is bad.

Slide 18

A milder allelic variant of Menkes disease, the occipital horn syndrome, occurs due to a molecular defect of leaky splice junction or hyomorphic missense mutations in ATP7A gene, with 20-30% residual activity. Symptoms observed include dysautonomia related to dopamine-beta-hydroxylase deficiency and connective tissue.

Slide 19

Infantile and childhood copper toxicosis syndrome encompasses copper toxicosis occurring in infants and young children seen in many parts of the world, and is usually associated with high levels of hepatic copper, caused by high concentrations of copper in drinking water or food. Indian Childhood Cirrhosis(ICC), restricted to the Indian Subcontinent occurs in infants the infants who were fed milk stored in brass or copper containers. Characterized by increased hepatic, urinary and serum copper, with rapidly progressive liver cirrhosis. This has become rare due to education of families for not cooking,eating and serving in copper and brass vessels.Idiopathic copper toxicity is similar to ICC and has been named as ICC like disease but caused by high concentrations of copper in drinking water or food like the contaminated spring water in endemic Tyrolean infantile cirrhosis. It is also suspected to be a rare disorder due to unidentified genetic defect.

Slide 20

Promising modes of detection and therapy herald future directions. New born screening program is being developed to enable early detection and hence early treatment of patients for Menkes disease and Occipital horn syndrome. For therapeutic challenge adenovirus mediated gene therapy and liver directed gene therapy for Wilsons disease is being tried to enable a healthy life.